It’s Friday and I am still in Boston but heading back this afternoon. Here is what I’m reading:
- Biotech Executives Fret Over Hassles And Uncertainties Of ‘Right To Try’
- Biosimilars could still pack revenue-busting punch, analyst suggests
- Bluebird’s Upgraded Gene Therapy Shows Promise For Sickle Cell Patients
- Harnessing ‘rogue’ stem cells to grow healthy fat could help treat metabolic disorders
I hope everyone has a great weekend!
MattCorc 